CD20 antibody first-line treatment for marginal zone lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a targeted antibody therapy as the first treatment for people with marginal zone B-cell lymphoma. It aims to see if this approach can effectively control the disease with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of lymphoma called marginal zone B-cell lymphoma.
- You are 18 years or older.
- You need treatment for your lymphoma (it is active or causing symptoms).
- You have not received any previous cancer treatment for lymphoma (like chemotherapy or immunotherapy).
- Your overall health is good enough for treatment (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, rituximab and venetoclax, as a first treatment for marginal zone lymphoma that has not been treated before. The goal is to see if this drug pair is safe and effective.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as a first treatment for people with advanced marginal zone lymphoma. The goal is to see if this combination can help control the cancer without the need for chemotherapy.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hear when a new MZL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.